Chronic hepatitis B virus infections: New possibilities for antiviral therapy;Chronische hepatitis-B-virusinfecties: Nieuwe mogelijkheden voor antivirale therapie

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 37, 1999, Pages 1857-1861

  De Man, R A ^a   Honkoop, P ^a   Janssen, H L A ^a   Schalm, S W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RECOMBINANT ALPHA INTERFERON; VIRUS DNA;

ANTIVIRAL ACTIVITY; HEPATITIS B; HUMAN; IMMUNOSTIMULATION; ORAL DRUG ADMINISTRATION; REVIEW; VIRUS INHIBITION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0033546924     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Fattovich G. Natural course and prognosis of chronic hepatitis type B. Viral Hep Rev 1996;2:263-76.
2. Borg F ter, Kate FJ ten, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PM, et al. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis-B-e-antigen. Lancet 1998;351:1914-8.
3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
4. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5.
5. Billiau A. The mode of action of interferons in viral infections and their possible role in the control of hepatitis B. J Hepatol 1986;3 Suppl 2:S171-9.
6. Perrillo RP, Schiff ER, Davis GL, Bodenheimer jr HC, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
7. Janssen HLA, Berk L, Man RA de, Heijtink RA, Schalm SW. Antivirale behandeling met alpha-interferon bij 100 patiënten met chronische hepatitis B. Ned Tijdschr Geneeskd 1992;136:835-9.
8. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
9. Jongh FE de, Janssen HLA, Man RA de, Hop WCJ, Schalm SW, Blankenstein M van. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
10. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
11. Lau DTY, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7.
12. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis-B-e-antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997;26:1338-42.
13. Garcia G, Smith CI, Weissberg JI, Eisenberg M, Bissett J, Nair PV, et al. Adenide arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial. Ann Intern Med 1987;107:278-85.
14. Berk L, Schalm SW, Man RA de, Heijtink RA, Berthelot P, Brechot C, et al. Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. J Hepatol 1992; 14:305-9.
15. Janssen HLA, Berk L, Heijtink RA, Kate FJW ten, Schalm SW. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial. Hepatology 1993;17:383-8.
16. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-3.
17. Krogsgaard K, Christensen E, Bindslev N, Schalm SW, Andersen PK, Ring-Larsen H. Relation between treatment efficacy and cumulative dose of alpha-interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1996; 25:795-802.
18. Janssen HLA, Berk L, Schalm SW, Heijtink RA, Hess G, Rossol S, et al. Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B. Gut 1992;33:1094-8.
19. Janssen HLA, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, et al. Alpha-interferon for chronic hepatitis B infection. Increased efficacy of prolonged treatment. Hepatology 1999;30:238-43.
20. Janssen HLA, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decompensation associated with interferon alfa. European Concerted Action on Viral Hepatitis (Eurohep). BMJ 1993;306:107-8.
21. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 1987;ii:1175-8.
22. Janssen HLA, Berk L, Vermeulen M, Schalm SW. Seizures associated with low-dose alpha-interferon [letter]. Lancet 1990;336:1580.
23. Janssen HLA, Brouwer JT, Mast R van der, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-3.
24. Heeringa M, Honkoop P, Man RA de, Feenstra J, Smits CMH. Ernstige psychiatrische bijwerkingen van interferon alfa-2b. Ned Tijdschr Geneeskd 1998;142:1618-21.
25. Luscombe CA, Locarnini SA. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hep Rev 1996;2:1-35.
26. Marcellin P, Pouteau M, Loriot MA, Boyer N, Degos F, Cales P, et al. Adenine arabinoside 5′-monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication. Gut 1995;36:422-6.
27. Fried MW, Korenman JC, Di Bisceglic AM, Park Y, Waggoner JG, Mitsuya H, et al. A pilot study of 2′,3′-dideoxyinosine for the treatment of chronic hepatitis B. Hepatology 1992;16:861-4.
28. Fried MW, Fong TL, Swain MG, Park Y, Beames MP, Banks SM, et al. Therapy of chronic hepatitis B with a 6-month course of ribavirin. J Hepatol 1994;21:145-50.
29. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88: 8495-9.
30. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992;267:22414-20.
31. Heijtink RA, Kruining J, Wilde GA de, Balzarini J, Clercq E de, Schalm SW. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother 1994;38:2180-2.
32. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099-105.
33. Honkoop P, Man RA de, Scholte HR, Zondervan PE, Berg JWO van den, Rademakers LHPM, et al. Effect of lamivudine treatment on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology 1997;26:211-5.
34. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
35. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
36. Honkoop P, Man RA de, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997;17:103-6.
37. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
38. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
39. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-7.
40. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-2.
41. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type I reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
42. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S28-33.
43. Honkoop P, Niesters HGM, Man RA de, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-5.
44. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, Man RA de, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998;28:923-9.